Catalyst overview
Research summary
This catalyst tracks a Approved update for Baxdrostat in Resistant or uncontrolled hypertension. The expected timing is based on the latest available company guidance and may change.
Bax24, BaxHTN Trials. 10/7/25- Met primary endpoint in Ph3 trial. 12/2/25- FDA grants baxdrostat Priority Review; PDUFA decision in Q2 2026. 04/29/26:- BaxHTN/Bax24/BaxAsia filing accepted in China for resistant hypertension. 05/18/26:- FDA approved BAXFENDY (baxdrostat) for uncontrolled or resistant hypertension based on BaxHTN Ph3.
Verification
Confirm timing and program details against the company announcement or filing.